(FULC) Fulcrum Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3596161097
FULC: Muscle, Blood, Genetic, Disorder, Therapy
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company focuses on advancing treatments for rare and debilitating conditions, leveraging its expertise in small molecule therapeutics and fetal hemoglobin induction.
Its lead product candidate, losmapimod, is a small molecule inhibitor currently in Phase III clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disorder characterized by progressive muscle weakness and degeneration. The company is also developing pociredir, a fetal hemoglobin inducer, which is in Phase I clinical trials for the treatment of sickle cell disease and beta-thalassemia, severe hematologic disorders requiring innovative therapeutic approaches.
Fulcrum has established strategic collaborations to expand its pipeline. It partners with Acceleron Pharma Inc. to identify targets in pulmonary diseases, MyoKardia, Inc. to develop therapies for genetic cardiomyopathies, and Sanofi to co-develop and commercialize losmapimod for FSHD. These collaborations underscore its commitment to addressing a broad range of rare and serious diseases, including neuromuscular, muscular, CNS, and hematologic disorders.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum Therapeutics operates at the intersection of genetics and drug development, aiming to deliver transformative therapies for patients with limited treatment options.
3-Month Forecast: Based on technical and fundamental analysis, FULC is expected to face headwinds in the near term. The stock is trading below its SMA20 and SMA50, indicating bearish momentum. However, the relatively low ATR suggests moderate volatility. Fundamentally, the negative RoE and low P/B ratio highlight challenges in valuation and profitability. Short-term price stabilization is possible if the company demonstrates progress in its clinical pipeline or announces favorable collaborations.
Additional Sources for FULC Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
FULC Stock Overview
Market Cap in USD | 170m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2019-07-18 |
FULC Stock Ratings
Growth 5y | -75.4% |
Fundamental | -22.0% |
Dividend | 0.0% |
Rel. Strength Industry | -72.3 |
Analysts | 3.29/5 |
Fair Price Momentum | 2.25 USD |
Fair Price DCF | - |
FULC Dividends
No Dividends PaidFULC Growth Ratios
Growth Correlation 3m | -88% |
Growth Correlation 12m | -70.5% |
Growth Correlation 5y | -67.8% |
CAGR 5y | -21.44% |
CAGR/Max DD 5y | -0.23 |
Sharpe Ratio 12m | -0.65 |
Alpha | -74.66 |
Beta | -0.25 |
Volatility | 82.51% |
Current Volume | 730.2k |
Average Volume 20d | 391.5k |
As of March 15, 2025, the stock is trading at USD 3.12 with a total of 730,246 shares traded.
Over the past week, the price has changed by -0.64%, over one month by -15.45%, over three months by -29.41% and over the past year by -72.09%.
Neither. Based on ValueRay Fundamental Analyses, Fulcrum Therapeutics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -21.99 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FULC as of March 2025 is 2.25. This means that FULC is currently overvalued and has a potential downside of -27.88%.
Fulcrum Therapeutics has received a consensus analysts rating of 3.29. Therefor, it is recommend to hold FULC.
- Strong Buy: 1
- Buy: 1
- Hold: 4
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, FULC Fulcrum Therapeutics will be worth about 2.4 in March 2026. The stock is currently trading at 3.12. This means that the stock has a potential downside of -22.12%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 5.7 | 81.7% |
Analysts Target Price | 5.7 | 81.7% |
ValueRay Target Price | 2.4 | -22.1% |